H3 Biomedicine and Selvita extend collaboration

Privately-held US biopharma group H3 Biomedicine and Poland’s leading biotech company Selvita (PL: SLV) have extended their strategic collaboration to develop breakthrough precision medicines for cancers through September 2016.

As part of the original collaboration begun in September 2013, the companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets. The companies are seeking to make further progress towards the initiation of Investigational New Drug (IND)-enabling studies during 2016. The results from both programs will be presented at scientific conferences in the first half of 2016.

“We are pleased to announce the extension of our collaboration with Selvita. Together we have continued to validate targets within a specific genomic context, which is at the core of H3's vision and mission,” said Markus Warmuth, president and chief executive of H3 Biomedicine, adding: “The strength of the combined teams has allowed for rapid advancement of the biology and chemistry in parallel. We look forward to further advancing the programs from discovery to translation over the next year.”